Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
78
mi
from 43215
Lima, OH
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
78
mi
from 43215
Lima, OH
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
793
mi
from 43215
Ponca City, OK
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
2006
mi
from 43215
Mountlake Terrace, WA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2006
mi
from 43215
Mountlake Terrace, WA
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Status: Archived
Children's Hospital Central California
1995
mi
from 43215
Madera, CA
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Status: Archived
Updated: 1/1/1970
Children's Hospital Central California
1995
mi
from 43215
Madera, CA
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Status: Archived
University of Chicago
270
mi
from 43215
Chicago, IL
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population
Status: Archived
Updated: 1/1/1970
University of Chicago
270
mi
from 43215
Chicago, IL
Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Use of Altabax Ointment (Retapamulin 1%) BID for 5 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study
Status: Archived
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis
Use of Altabax Ointment (Retapamulin 1%) BID for 5 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study
Status: Archived
Updated: 1/1/1970
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
Acupressure in Pruritus for Atopic Dermatitis
Evaluating the Effectiveness of Acupressure in Relieving Pruritus Related to Atopic Dermatitis
Status: Archived
Northwestern University
274
mi
from 43215
Chicago, IL
Acupressure in Pruritus for Atopic Dermatitis
Evaluating the Effectiveness of Acupressure in Relieving Pruritus Related to Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
Northwestern University
274
mi
from 43215
Chicago, IL
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
188
mi
from 43215
Louisville, KY
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
188
mi
from 43215
Louisville, KY
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2060
mi
from 43215
Medford, OR
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
525
mi
from 43215
Charleston, SC
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
525
mi
from 43215
Charleston, SC
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
344
mi
from 43215
Richmond, VA
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
344
mi
from 43215
Richmond, VA
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Trial Facility
330
mi
from 43215
Milwaukee, WI
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
330
mi
from 43215
Milwaukee, WI
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Therapeutics Clinical Research
1947
mi
from 43215
San Diego, CA
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Therapeutics Clinical Research
1947
mi
from 43215
San Diego, CA
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Michigan Center for Skin Care Research
182
mi
from 43215
Clinton Township, MI
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Michigan Center for Skin Care Research
182
mi
from 43215
Clinton Township, MI
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Somerset Skin Care Center
179
mi
from 43215
Troy, MI
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Somerset Skin Care Center
179
mi
from 43215
Troy, MI
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
David Fivenson, M.D. Dermatology, PLLC
164
mi
from 43215
Ann Arbor, MI
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
David Fivenson, M.D. Dermatology, PLLC
164
mi
from 43215
Ann Arbor, MI
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Derm Research, Inc
1059
mi
from 43215
Austin, TX
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Derm Research, Inc
1059
mi
from 43215
Austin, TX
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
492
mi
from 43215
Birmingham, AL
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2093
mi
from 43215
Santa Clara, CA
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Celebration, FL
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
416
mi
from 43215
Philadelphia, PA
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
A Study of RO5310074 in Patients With Psoriatic Arthritis
A Multi-center, Randomized, Observer-blinded, Multiple-Ascending-Dose, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5310074 Following Multiple Intravenous Administrations in Subjects With Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis
Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis
Status: Archived
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis
Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Compliant Clinical Research of Wichita, Inc.
779
mi
from 43215
Wichita, KA
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Compliant Clinical Research of Wichita, Inc.
779
mi
from 43215
Wichita, KA
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
DermResearch, PLLC
189
mi
from 43215
Louisville, KY
A Study to Determine the Optimal Dose of SCH 900222 for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (Study P05495)
Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)
Status: Archived
Clinical Research Facility
2029
mi
from 43215
Lake Oswego, OR
A Study to Determine the Optimal Dose of SCH 900222 for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (Study P05495)
Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2029
mi
from 43215
Lake Oswego, OR
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
An Open-Label Evaluation of the Adrenal Suppression Potential of Product 0405 in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects
Status: Archived
Nycomed US Inc.
509
mi
from 43215
Melville, NY
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
An Open-Label Evaluation of the Adrenal Suppression Potential of Product 0405 in the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Subjects
Status: Archived
Updated: 1/1/1970
Nycomed US Inc.
509
mi
from 43215
Melville, NY
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
An Open-Label Pilot Study to Determine the Efficacy and Tolerability of a Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis With Associated Pruritus in Adults
Status: Archived
Dermatology Consulting Services
321
mi
from 43215
High Point, NC
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
An Open-Label Pilot Study to Determine the Efficacy and Tolerability of a Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis With Associated Pruritus in Adults
Status: Archived
Updated: 1/1/1970
Dermatology Consulting Services
321
mi
from 43215
High Point, NC
Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis
The Atopic Dermatitis Clinic as an Entry Point for Community Outreach in Asthma, Missed Immunizations, and Vitamin D Deficiency
Status: Archived
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis
The Atopic Dermatitis Clinic as an Entry Point for Community Outreach in Asthma, Missed Immunizations, and Vitamin D Deficiency
Status: Archived
Updated: 1/1/1970
Childrens Hospital Los Angeles
1973
mi
from 43215
Los Angeles, CA
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
970
mi
from 43215
Fort Lauderdale, FL
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
970
mi
from 43215
Fort Lauderdale, FL
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
282
mi
from 43215
Evanston, IL
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
282
mi
from 43215
Evanston, IL
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
1333
mi
from 43215
Albuquerque, NM
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1333
mi
from 43215
Albuquerque, NM
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Clinical Research Facility
1967
mi
from 43215
Bend, OR
Study to Evaluate the Efficacy, and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1967
mi
from 43215
Bend, OR